NVCR News and Press, NovoCure Limited From 10/28/21

Novocure (NASDAQ:NVCR) announces that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields ((TTFields)) together with paclitaxel for treatment of patients with platinum-resistant ovarian cancer. Following the completion of en...

Quarterly net revenues of $133.6 million with 77% gross margin Last patient enrolled in phase 3 pivotal INNOVATE-3 trial for recurrent ovarian cancer Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2021, highlighting comme...

Final data from INNOVATE-3 trial anticipated in 2023 Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with paclitaxel for treatment of pat...

Highlights include presentations by external authors studying the effects of concurrent Tumor Treating Fields and chemoradiation for patients with newly diagnosed glioblastoma Novocure (NASDAQ: NVCR) today announced 15 presentations on Tumor Treating Fields (TTFields) will b...

The stock market loves instant gratification. When forced to wait for a potentially good thing to pay off, some traders can begin to lose interest. Cancer treatment company Novocure (NASDAQ: NVCR) , which uses low-power electrical fields to disrupt the growth of cancer cells , i...

Aggressive forms of cancer can be devastating to patients and their families. This kind of diagnosis brings uncertainties about the quality of life and the length of time a patient has left. Healthcare company Novocure (NASDAQ: NVCR) aims to improve both these aspects for patien...

Margetuximab, a monoclonal antibody for HER2+ breast cancer under development from Zai Lab (NASDAQ:ZLAB), met its primary endpoint in a phase 2 study in previously treated patients in China. The primary endpoint was median progression-free survival. The hazard ratio for progression-free survi...

Zai Lab (NASDAQ:ZLAB) and Novocure (NASDAQ:NVCR) announces that the final patient has been enrolled in the phase 2 pilot trial evaluating the safety and efficacy of Tumor Treating Fields ((TTFields)) in combination with chemotherapy as a first-line treatment in patients with gastric aden...

Final data collection is expected in the first half of 2022 SHANGHAI and St. Helier, JERSEY, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology com...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2021 on Thursday, October 28, 2021, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the t...